Conditions: Richter's Transformation
Keywords: PNT2258 Richter's Transformation NHL Non-Hodgkin's Lymphoma Lymphoma DLBCL Diffuse Large B-cell Lymphoma Lymphoma, Large B-cell, Diffuse Lymphoma, Non-Hodgkin Lymphoma, B-cell
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 5
Healthy volunteers: no

Brief summary:
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, single-arm, 2-stage, open-label phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with Richter's Transformation.

Detailed description:

Arms:
arm 1: PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle for 8 induction cycles followed by continuation phase therapy at a dose of 100 mg/m2 on days 1-4 of a 28-day cycle.

Interventions: intervention 1: PNT2258
Intervention descriptions: intervention 1: None

Protocol document: